Last $3.35 USD
Change Today -0.12 / -3.46%
Volume 323.5K
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $6.69
52 Week Low
12/9/14 - $2.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases; and a collaboration agreement with Biocept, Inc. to evaluate microRNAs from circulating tumor cells. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

45 Employees
Last Reported Date: 03/31/14
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosetta genomics ltd (ROSG) Key Developments

Rosetta Seeks Acquisitions

Rosetta Genomics, Ltd. (NasdaqCM:ROSG) is looking for acquisition opportunities. In a Securities and Exchange Commission filing, Rosetta said it entered into the agreement with Cantor Fitzgerald & Co. and under the agreement Rosetta may offer and sell ordinary shares, par value NIS 0.6 per share from time to time through Cantor. Rosetta intends to file a prospectus supplement relating to the offer and sale, from time to time, of its ordinary shares having an aggregate offering price of up to $14.4 million pursuant to the agreement. Net proceeds will be used for corporate purposes including repayment or refinancing of future indebtedness or other future corporate borrowings, working capital, IP protection and enforcement, capital expenditures, investments, acquisitions and product development.

Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics

Rosetta Genomics Ltd. announced that the company has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio's oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C., with an expectation to expand nationally over time.

Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance

Rosetta Genomics Ltd. and Marina Biotech, Inc. jointly announced the initiation of the first project under the strategic alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD). In this study, Rosetta will evaluate archived muscle biopsy samples from 10-30 DMD patients and 10-30 non-DMD controls. The samples will be processed and assessed by Rosetta's microarray platform. Samples will also be profiled using deep sequencing to identify novel microRNAs and isomiRs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.35 USD -0.12

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $8.66 USD -0.10
Genomic Health Inc $30.70 USD -0.40
NeoGenomics Inc $4.61 USD +0.06
Response Genetics Inc $0.55 USD -0.02
Veracyte Inc $8.61 USD -0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at